摘要
目的 :探讨低分子肝素吉哌啉对肾病综合征的治疗作用 ;方法 :3 9例原发性肾病综合征按治疗方法分为两组 :A组为观察组 ,共 2 0例 ,B组为对照组 ,共 1 9例 ,两组患者均给予钙离子拮抗剂 ,强的松 1mg/ (kg·d)顿服 ,视病情用 6周～ 8周 ,环磷酰胺 2 0 0mg隔日一次静脉注射 ,视病情用量 6g～ 8g。A组加用低分子肝素吉哌啉 50 0 0u +生理盐水40ml静脉注射 2 0天～ 2 5天为一疗程 ;结果 :治疗后 2 4小时尿蛋白定量A组较B组显著减少 (0 .82 g± 0 .64 gVS 1 .99g± 0 .85g,P <0 .0 1 ) ,治疗后血浆白蛋白定量A组较B组有明显回升 (3 1 .8g/L± 5.77g/LVS 2 7.3 6g/L± 7.55g/L ,P <0 .0 5) ,说明A组疗效优于B组 ;结论 :低分子肝素吉哌啉在治疗肾病综合征中的抗凝作用减轻了肾小球基膜阴离子电荷的损伤 ,最终可减少尿蛋白的排出 ,增强治疗肾病综合征的疗效。
Objective:To describe the therapeutic effects of low molecular heparin on nephropathy syndrome.Methods:39 patients with primary nephropathy syndrome were divided into the A group (20 cases) in which low molecular heparin combined with calcium antagonist+predinison+cyclophosphamide was given, and B group (19cases),the calcium antagonist+predinison+cyclophosphamide was given in clinic.The treated effects were recorded.Results: The level of urine protein in A group was lower ( 0.82g±0.64g) than that in B group (1.99g±0.85g) (P<0.01) after 24h treatment and the plasma level of protein was higher in A group than that in B group (P<0.05).Conclusion: The low molecular heparin could increase a better effect of treatment with calcium antagonist+predinison+cyclophosphamide in nephropathy syndrome due to its anticaogulant active.
出处
《青海医药杂志》
2003年第6期5-6,共2页
Qinghai Medical Journal
